Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease.
Socinski MA, Kaye FJ, Spigel DR, Kudrik FJ, Ponce S, Ellis PM, Majem M, Lorigan P, Gandhi L, Gutierrez ME, Nepert D, Corral J, Ares LP. Socinski MA, et al. Among authors: kaye fj. Clin Lung Cancer. 2017 Jan;18(1):68-76.e2. doi: 10.1016/j.cllc.2016.09.002. Epub 2016 Oct 3. Clin Lung Cancer. 2017. PMID: 28341109 Free article. Clinical Trial.
Phase II neoadjuvant trial of paclitaxel by 96-hour continuous infusion (CIVI) in combination with cisplatin followed by chest radiotherapy for patients with stage III non-small-cell lung cancer.
Breathnach OS, Kasturi V, Kaye F, Herscher L, Georgiadis MS, Edison M, Schuler BS, Pizzella P, Steinberg SM, O'Neil K, Johnson BE. Breathnach OS, et al. Am J Clin Oncol. 2002 Jun;25(3):269-73. doi: 10.1097/00000421-200206000-00013. Am J Clin Oncol. 2002. PMID: 12040286 Clinical Trial.
Significantly mutated genes and regulatory pathways in SCLC-a meta-analysis.
Sundaresan V, Lin VT, Liang F, Kaye FJ, Kawabata-Iwakawa R, Shiraishi K, Kohno T, Yokota J, Zhou L. Sundaresan V, et al. Among authors: kaye fj. Cancer Genet. 2017 Oct;216-217:20-28. doi: 10.1016/j.cancergen.2017.05.003. Epub 2017 Jun 7. Cancer Genet. 2017. PMID: 29025592 Free PMC article.
Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.
Kellish P, Shabashvili D, Rahman MM, Nawab A, Guijarro MV, Zhang M, Cao C, Moussatche N, Boyle T, Antonia S, Reinhard M, Hartzell C, Jantz M, Mehta HJ, McFadden G, Kaye FJ, Zajac-Kaye M. Kellish P, et al. Among authors: kaye fj. J Clin Invest. 2019 Apr 29;129(6):2279-2292. doi: 10.1172/JCI121323. eCollection 2019 Apr 29. J Clin Invest. 2019. PMID: 31033480 Free PMC article.
Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.
Creelan BC, Wang C, Teer JK, Toloza EM, Yao J, Kim S, Landin AM, Mullinax JE, Saller JJ, Saltos AN, Noyes DR, Montoya LB, Curry W, Pilon-Thomas SA, Chiappori AA, Tanvetyanon T, Kaye FJ, Thompson ZJ, Yoder SJ, Fang B, Koomen JM, Sarnaik AA, Chen DT, Conejo-Garcia JR, Haura EB, Antonia SJ. Creelan BC, et al. Among authors: kaye fj. Nat Med. 2021 Aug;27(8):1410-1418. doi: 10.1038/s41591-021-01462-y. Epub 2021 Aug 12. Nat Med. 2021. PMID: 34385708 Free PMC article. Clinical Trial.
144 results